Harnessing the MYB-dependent TAL1 5'super-enhancer for targeted therapy in T-ALL

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Cancer development is driven by genetic abnormalities that lead to oncogene dysregulation.
• Various proto-oncogenes have multiple dysregulation mechanisms, but their distinct clinical impacts remain largely unknown.
• T-cell acute lymphoblastic leukemia (T-ALL) serves as a model to investigate these mechanisms.

Discussion:

• Patients with 5'super-enhancer (5'SE) mutations in the TAL1 oncogene represent a distinct subgroup with poor prognosis in T-ALL.
• This poor prognosis is observed regardless of the overall level of oncogene dysregulation.
• The MYB-dependent oncogenic 5'SE is a targetable mechanism in T-ALL.

Key Insights:

• Targeting the MYB-dependent 5'SE with Mebendazole induces MYB protein degradation, leading to T-ALL cell death.
• Mebendazole demonstrated efficacy in preclinical T-ALL models.
• The mechanism of oncogene dysregulation, not just the oncogene, can define distinct clinical subgroups in cancer.

Outlook:

• This study provides proof of concept for targeting super-enhancers in oncogene-driven cancers.
• Super-enhancer targeting therapy offers a promising avenue for future cancer treatment strategies.
• Identifying specific dysregulation mechanisms can lead to more precise patient stratification and personalized therapies.